Iclusig (Ponatinib) - Chronic Myeloid Leukemia - CML
SITES
Ponatinib (Ariad)
FORUMS
Ponatinib by LLS Group discussion
Iclusib by CML2 support group
Ponatinib by NewCMLDrug.Com
Ponatinib on Facebook
BLOGS
Hans’s Blog
CLINICAL TRIALS
Ponatinib for CML Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) (PACE)
Expanded Access Program of Ponatinib
Ponatinib for CML Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) (PACE)
Expanded Access Program of Ponatinib
ARTICLES
“Borne Out of Necessity and Data”: Conquering Mutations in Leukemia
February 6, 2013, PLOS Blog
New TKI Ponatinib Effective in Resistant CML
February 2013, Clinical Oncology News
Ponatinib Could Herald “Revolution”in CML Treatment
December 20, 2012, OncLive
Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
November 29, 2012, The New England Journal of Medicine
F.D.A. Gives Early Approval to Drug for Rare Leukemia
December 14, 2012, The New York Times
OHSU-developed ponatinib wins FDA approval
December 14, 2012, Portland Business Journal
FDA grants approval for potential ‘blockbuster’ leukemia drug made by Cambridge-based Ariad
December 14, 2012, Boston.com
FDA Approves Ponatinib to Treat Leukemia
December 14, 2012, Cancer Network
ARIAD Announces Accelerated Approval by FDA of Iclusig (Ponatinib) for Patients with CML and Ph+ ALL Resistant or
Intolerant to Prior Tyrosine Kinase Inhibitor Therapy
December 14, 2012, Ariad
FDA Approves Ariad Pharma Leukemia Drug
December 14, 2012, The Street
Study Brings Positive Results For the Most Resistant Types of CML VIDEO
December 12, 2012, Patient Power
Ponatinib offers new hope in drug-resistant leukemia
December 5, 2012 , News-Medical.net
Chronic Myeloid Leukemia Mutation Thwarted By Ponatinib
December 2, 2012, Science 2.0
Data Published on ARIAD Candidate - Analyst Blog
November 30, 2012, Nasdaq
In CML, Next-Generation TKIs Aim to Boost Outcomes
November 30, 2012, Onc LIve
Ponatinib - New Pill Could Do Wonders for Cancer Patients
November 30, 2012, FM NEWS 101 KXL
Ponatinib - Cancer pill targets previously impenetrable disease-causing gene mutation in leukemia patients
November 29, 2012, OHSU
Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia
November 29, 2012, News Medical
Ponatinib for Chronic Myeloid Leukemia
November 29, 2012, The New England Journal of Medicine
Ponatinib acts against the most resistant types of chronic myeloid leukemia
November 28, 2012, Science Codex
Ponatinib Acts Against the Most Resistant Types of Chronic Myeloid Leukemia
November 28, 2012, Science Daily
Ariad CEO discusses company’s battle against cancer
November 8, 2012, Boston Herald
PropThink: Management says Ariad is Well-Prepared for Ponatinib Launch
November 7, 2012, Reuters
FDA Agrees to Speed Review of Ariad Drug
October 25, 2012, DailyFinance
Ariad: FDA doing priority review of leukemia drug
October 23, 2012, CBSNews.com
Ariad Pharma downgraded on gains over last year
October 23, 2012, CBS News
PropThink: ARIAD Building an Oncology Business Around Discovery, Development, and Commercialization
October 4, 2012, Reuters
Ariad Pharmaceuticals: Ponatinib Approval Anticipated In Second-Line CML
October 1, 2012, Seeking Alpha
ARIAD Announces Submission of Marketing Authorization Application for Ponatinib to the European Medicines Agency
August. 30, 2012, ARIAD Pharmaceuticals, Inc.
Ariad seeks approval for leukemia drug in Europe
August 30, 2012, MHT
Ariad Pharmaceuticals Gearing Up For Ponatinib's Approval
August 29, 2012, Seeking Alpha
ARIAD Pharma initiates phase I/II trial of ponatinib in Japan
August 22, 2012, Pharmabiz.com
Ponatinib Produces High Response Rates in CML
August 13, 2012, New Mexico Cancer Center
Accelerated FDA Approval for CML Drug Ponatinib Sought
August 9, 2012, Cancer Network
Ponatinib Achieves Primary Endpoints in CML Subtypes
August 8, 2012, OncLive
Ariad Prepares for Early Launch of CML Drug Ponatinib
August 6, 2012, Oncology Stat
Ariad speeds targeted leukemia drug to FDA in race for key approval
July 31, 2012, FierceBiotech
Ariad Pharma ANNOUNCES Phase 3 Trial and 4 Stocks Hitting 52-Week Highs
July 28, 2012, Wall St . Cheqt Sheet
Dr. Jorge Cortes Discusses the Ponatinib Ph+All and CML Evaluation (PACE) Trial VIDEO
June 14, 2012, OncLive
Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy
April 24, 2012, Haematologica
ARIAD: Xiaotian Zhu on Ponatinib VIDEO
April 3, 2012, Executive video
“Borne Out of Necessity and Data”: Conquering Mutations in Leukemia
February 6, 2013, PLOS Blog
New TKI Ponatinib Effective in Resistant CML
February 2013, Clinical Oncology News
Ponatinib Could Herald “Revolution”in CML Treatment
December 20, 2012, OncLive
Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
November 29, 2012, The New England Journal of Medicine
F.D.A. Gives Early Approval to Drug for Rare Leukemia
December 14, 2012, The New York Times
OHSU-developed ponatinib wins FDA approval
December 14, 2012, Portland Business Journal
FDA grants approval for potential ‘blockbuster’ leukemia drug made by Cambridge-based Ariad
December 14, 2012, Boston.com
FDA Approves Ponatinib to Treat Leukemia
December 14, 2012, Cancer Network
ARIAD Announces Accelerated Approval by FDA of Iclusig (Ponatinib) for Patients with CML and Ph+ ALL Resistant or
Intolerant to Prior Tyrosine Kinase Inhibitor Therapy
December 14, 2012, Ariad
FDA Approves Ariad Pharma Leukemia Drug
December 14, 2012, The Street
Study Brings Positive Results For the Most Resistant Types of CML VIDEO
December 12, 2012, Patient Power
Ponatinib offers new hope in drug-resistant leukemia
December 5, 2012 , News-Medical.net
Chronic Myeloid Leukemia Mutation Thwarted By Ponatinib
December 2, 2012, Science 2.0
Data Published on ARIAD Candidate - Analyst Blog
November 30, 2012, Nasdaq
In CML, Next-Generation TKIs Aim to Boost Outcomes
November 30, 2012, Onc LIve
Ponatinib - New Pill Could Do Wonders for Cancer Patients
November 30, 2012, FM NEWS 101 KXL
Ponatinib - Cancer pill targets previously impenetrable disease-causing gene mutation in leukemia patients
November 29, 2012, OHSU
Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia
November 29, 2012, News Medical
Ponatinib for Chronic Myeloid Leukemia
November 29, 2012, The New England Journal of Medicine
Ponatinib acts against the most resistant types of chronic myeloid leukemia
November 28, 2012, Science Codex
Ponatinib Acts Against the Most Resistant Types of Chronic Myeloid Leukemia
November 28, 2012, Science Daily
Ariad CEO discusses company’s battle against cancer
November 8, 2012, Boston Herald
PropThink: Management says Ariad is Well-Prepared for Ponatinib Launch
November 7, 2012, Reuters
FDA Agrees to Speed Review of Ariad Drug
October 25, 2012, DailyFinance
Ariad: FDA doing priority review of leukemia drug
October 23, 2012, CBSNews.com
Ariad Pharma downgraded on gains over last year
October 23, 2012, CBS News
PropThink: ARIAD Building an Oncology Business Around Discovery, Development, and Commercialization
October 4, 2012, Reuters
Ariad Pharmaceuticals: Ponatinib Approval Anticipated In Second-Line CML
October 1, 2012, Seeking Alpha
ARIAD Announces Submission of Marketing Authorization Application for Ponatinib to the European Medicines Agency
August. 30, 2012, ARIAD Pharmaceuticals, Inc.
Ariad seeks approval for leukemia drug in Europe
August 30, 2012, MHT
Ariad Pharmaceuticals Gearing Up For Ponatinib's Approval
August 29, 2012, Seeking Alpha
ARIAD Pharma initiates phase I/II trial of ponatinib in Japan
August 22, 2012, Pharmabiz.com
Ponatinib Produces High Response Rates in CML
August 13, 2012, New Mexico Cancer Center
Accelerated FDA Approval for CML Drug Ponatinib Sought
August 9, 2012, Cancer Network
Ponatinib Achieves Primary Endpoints in CML Subtypes
August 8, 2012, OncLive
Ariad Prepares for Early Launch of CML Drug Ponatinib
August 6, 2012, Oncology Stat
Ariad speeds targeted leukemia drug to FDA in race for key approval
July 31, 2012, FierceBiotech
Ariad Pharma ANNOUNCES Phase 3 Trial and 4 Stocks Hitting 52-Week Highs
July 28, 2012, Wall St . Cheqt Sheet
Dr. Jorge Cortes Discusses the Ponatinib Ph+All and CML Evaluation (PACE) Trial VIDEO
June 14, 2012, OncLive
Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy
April 24, 2012, Haematologica
ARIAD: Xiaotian Zhu on Ponatinib VIDEO
April 3, 2012, Executive video
Dr. Jorges Cortes: ASH2011 - Two New Winners for CML? VIDEO
December 23, 2011, Medscape News Today
Ariad Pharmaceuticals Still Might Have Upside
December 21, 2011, Investor Place
Waging War Against Chronic Myeloid Leukemia
Chronic Myeloid Leukema responds well to experimental drug ponatinib
December 20, 2011, DailyRX
Ariad's ponatinib takes center stage with promising pivotal leukemia data
December 12, 2011, Fierce Biotech
Drug For Chronic Myeloid Leukemia To Be Out Soon
December 12, 2011, TopNews
Initial Findings from the PACE trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+All
Resistant or Intolerant or Dasatinib or Nilotinib, or with the T315I Mutation
December 2, 2011, Ariad
Ariad Pharma: Early Efficacy, Safety of Leukemia Drug 'Striking'
November 7, 2011, The Street
ARIAD Presents New Preclinical Data On Ponatinib In Solid Tumors, Demonstrating Inhibition Of All FGF Receptor Kinases
April 6, 2011, Medical News Today
Phase I Trial Shows Ponatinib May Thwart Most Resistant CML
December 16, 2010, MD Anderson Cancer Center - Department of Leukemia
Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH
December 6, 2010 , News medical
Novel CML Drug Active After Failures of Imatinib, Dasatinib, and Nilotinib
December 6, 2010, Oncology Stat
Phase I Trial Indicates Ponatinib May Thwart Most Resistant CML
December 2010, Drugs.com
ARIAD Announces Initiation Of Ponatinib (AP24534) Pivotal Trial In Drug-Resistant Or Intolerant Chronic Myeloid Leukemia
September 2010, Medical News Today
Phase 2 trial of ponatinib for the treatment of chronic myeloid leukemia (CML) and Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL)
September 2010, MPR
December 23, 2011, Medscape News Today
Ariad Pharmaceuticals Still Might Have Upside
December 21, 2011, Investor Place
Waging War Against Chronic Myeloid Leukemia
Chronic Myeloid Leukema responds well to experimental drug ponatinib
December 20, 2011, DailyRX
Ariad's ponatinib takes center stage with promising pivotal leukemia data
December 12, 2011, Fierce Biotech
Drug For Chronic Myeloid Leukemia To Be Out Soon
December 12, 2011, TopNews
Initial Findings from the PACE trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+All
Resistant or Intolerant or Dasatinib or Nilotinib, or with the T315I Mutation
December 2, 2011, Ariad
Ariad Pharma: Early Efficacy, Safety of Leukemia Drug 'Striking'
November 7, 2011, The Street
ARIAD Presents New Preclinical Data On Ponatinib In Solid Tumors, Demonstrating Inhibition Of All FGF Receptor Kinases
April 6, 2011, Medical News Today
Phase I Trial Shows Ponatinib May Thwart Most Resistant CML
December 16, 2010, MD Anderson Cancer Center - Department of Leukemia
Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH
December 6, 2010 , News medical
Novel CML Drug Active After Failures of Imatinib, Dasatinib, and Nilotinib
December 6, 2010, Oncology Stat
Phase I Trial Indicates Ponatinib May Thwart Most Resistant CML
December 2010, Drugs.com
ARIAD Announces Initiation Of Ponatinib (AP24534) Pivotal Trial In Drug-Resistant Or Intolerant Chronic Myeloid Leukemia
September 2010, Medical News Today
Phase 2 trial of ponatinib for the treatment of chronic myeloid leukemia (CML) and Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL)
September 2010, MPR
